Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 7, 2009, Pages 611-613

  Skeppholm, Mika ^a,d   Wallén, N Håkan ^a   Mobarrez, Fariborz ^a   Sollevi, Alf ^c   Soop, Anne ^c   Antovic, Jovan P ^b  

^a Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ELASTASE; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BLOOD SAMPLING; BODY WEIGHT; DILUTION; ENDOTOXEMIA; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPERIMENTAL STUDY; HUMAN; INFLAMMATION; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; THROMBIN TIME; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; MALE; PATHOLOGY; YOUNG ADULT;

CARBOXYPEPTIDASE U; ENDOTOXEMIA; ENDOTOXINS; ESCHERICHIA COLI; HUMANS; INFLAMMATION; MALE; THROMBIN; YOUNG ADULT; CARBOXYPEPTIDASE B2;

EID: 70349799009     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833161c5     Document Type: Letter

References (12)

1. Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis (review). Clin Lab 2003; 49:475-486.
2. Boffa BM, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40:431-442.
3. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165:1053-1058.
4. Silveira A, Schatterman K, Goossens F, Moor E, Scharpé S, Strömqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84:364-368.
5. Rooth E, Wallén H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinol 2007; 18:365-370.
6. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104:1-6.
7. Ungerstedt JS, Soop A, Sollevi A, Blombäck M. Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxin. Thromb Res 2003; 111:329-334.
8. Soop A, Albert J, Weitzberg E, Bengtsson A, Nilsson C-G, Sollevi A. Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia. Clin Exp Immunol 2004; 135:114-118.
9. Li N, Soop A, Sollevi A, Hjemdahl P. Multicellular activation in vivo by endotoxin in humans: limited protection by adenosine infusion. Thromb Haemost 2000; 84:381-387.
10. Kawamura T, Okada N, Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 2002; 46:225-230.
11. Verbon A, Meijers JCM, Spek A, Hack CE, Pribble JP, Turner T, et al. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis 2003; 187:55-61.
12. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118:205-212.